Kilogram scale facile synthesis and systematic characterization of a Gd-macrochelate as T1-weighted magnetic resonance imaging contrast agent
Open Access
- 9 April 2024
- journal article
- research article
- Published by Springer Nature in Journal of Nanobiotechnology
- Vol. 22 (1) , 1-15
Abstract
To overcome the problems of commercial magnetic resonance imaging (MRI) contrast agents (CAs) (i.e., small molecule Gd chelates), we have proposed a new concept of Gd macrochelates based on the coordination of Gd3+ and macromolecules, e.g., poly(acrylic acid) (PAA). To further decrease the r2/r1 ratio of the reported Gd macrochelates that is an important factor for T1 imaging, in this study, a superior macromolecule hydrolyzed polymaleic anhydride (HPMA) was found to coordinate Gd3+. The synthesis conditions were optimized and the generated Gd-HPMA macrochelate was systematically characterized. The obtained Gd-HPMA29 synthesized in a 100 L of reactor has a r1 value of 16.35 mM−1 s−1 and r2/r1 ratio of 2.05 at 7.0 T, a high Gd yield of 92.7% and a high product weight (1074 g), which demonstrates the feasibility of kilogram scale facile synthesis. After optimization of excipients and sterilization at a high temperature, the obtained Gd-HPMA30 formulation has a pH value of 7.97, osmolality of 691 mOsmol/kg water, density of 1.145 g/mL, and viscosity of 2.2 cP at 20 ℃ or 1.8 cP at 37 ℃, which meet all specifications and physicochemical criteria for clinical injections indicating the immense potential for clinical applications. Graphical AbstractKeywords
Funding Information
- Guangzhou Key Research and Development Program of China (202103000094)
- National Natural Science Foundation of China (32271374)
- Guangdong Provincial Natural Science Foundation of China (2414050003780)
This publication has 44 references indexed in Scilit:
- Facile Synthesis of Weakly Ferromagnetic Organogadolinium Macrochelates‐Based T1‐Weighted Magnetic Resonance Imaging Contrast AgentsAdvanced Science, 2022
- Risk of Nephrogenic Systemic Fibrosis in Patients With Stage 4 or 5 Chronic Kidney Disease Receiving a Group II Gadolinium-Based Contrast AgentJAMA Internal Medicine, 2020
- Structure–Relaxivity Relationships of Magnetic Nanoparticles for Magnetic Resonance ImagingAdvanced Materials, 2019
- Gadolinium Retention After Contrast-Enhanced MRIJAMA, 2018
- Intracranial Gadolinium Deposition Following Gadodiamide-Enhanced Magnetic Resonance Imaging in Pediatric PatientsJAMA Pediatrics, 2017
- Inorganic Nanoparticles for MRI Contrast AgentsAdvanced Materials, 2009
- High‐Relaxivity MRI Contrast Agents: Where Coordination Chemistry Meets Medical ImagingAngewandte Chemie International Edition, 2008
- MR contrast agents: Physical and pharmacologic basicsJournal of Magnetic Resonance Imaging, 2007
- Comparative study of the physicochemical properties of six clinical low molecular weight gadolinium contrast agentsContrast Media & Molecular Imaging, 2006
- Molecular Dynamics Simulations of MRI-Relevant GdIII Chelates: Direct Access to Outer-Sphere RelaxivityChemistry – A European Journal, 2001